Notably, MC38 and B16-OVA tumour growth was undisturbed by glutamine supplementation in Batf3–/– mice that lack cDC1s29 (Fig. 1l and Extended Data Fig. 1q), indicating that the beneficial effect of glutamine treatment requires cDC1s. This evidence concerns the gene BATF3 and neoplasm.